Content about Proteobacteria

December 11, 2012
Biotech company acquires vaccine from Pfizer

Biotech and vaccines company Nuron Biotech has bought rights from Pfizer for a vaccine to prevent infection by a bacteria that is a major cause of infectious disease around the world.

EXTON, Pa. — Biotech and vaccines company Nuron Biotech has bought rights from Pfizer for a vaccine to prevent infection by a bacteria that is a major cause of infectious disease around the world.

June 15, 2012
FDA approves MenHibrix

GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.

PHILADELPHIA — GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.

MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid conjugate vaccine) is approved for use in children ages six weeks through 18 months. The vaccination schedule is a four-dose series given at two, four, six, and 12 through 15 months of age.

March 14, 2012
Study: H. pylori may be linked to diabetes risk

A bacterium found in the stomach may be associated with diabetes, according to a study published in the Journal of Infectious Diseases.

NEW YORK — A bacterium found in the stomach may be associated with diabetes, according to a study published in the Journal of Infectious Diseases.

April 25, 2011
Menactra approved for use in infants, toddlers

The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

The FDA announced the approval of Menactra, made by Sanofi Pasteur, the vaccines arm of French drug maker Sanofi-Aventis. Meningococcal disease is a life-threatening illness caused by Neisseria meningitidis bacteria that infect the bloodstream and the lining surrounding the brain and spinal cord.

February 1, 2011
Novartis' Menveo approved for use in children

The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.

BASEL, Switzerland — The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.

Novartis announced the approval of Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) for active immunization to prevent certain forms of meningococcal disease caused by Neisseria meningitidis in children ages 2 to 10 years. The FDA approved the vaccine last year for use in adolescents and adults ages 11 to 55 years.

October 25, 2010
Novartis: Menveo protects infants against meningococcal disease

An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in...

BASEL, Switzerland An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in infants, according to results of a late-stage clinical trial released Monday.

 

The Swiss drug maker said results of a phase-3 trial showed that Menveo (meningococcal group A, C, W135 and Y) induced immune responses in a high percentage of babies against four strains of the bacteria. Meningococcal disease occurs suddenly and can cause serious illness and often death during the first year of life.

 

 

February 21, 2010
FDA approves Menveo

Novartis has received Food and Drug Administration approval for a vaccine for meningococcal disease, the...

CAMBRIDGE, Mass. Novartis has received Food and Drug Administration approval for a vaccine for meningococcal disease, the Swiss drug maker’s vaccines division announced Monday.

The FDA approved Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197) to prevent meningococcal disease caused by Neisseria meningitidis bacteria.

 

January 3, 2010
Bacterial protein mimics its host to disable a key enzyme

Helicobacter pylori, an infection that causes gastric ulcers and cancers of the gut, may be...